Real‐life second‐line epirubicin–paclitaxel regimen as treatment of relapsed small‐cell lung cancer: EpiTax study
Abstract Background Few therapeutic options are approved as second‐line treatment after failure of platinum‐based chemotherapy for patients with extensive‐stage small‐cell lung cancer (ES‐SCLC). Topotecan widespread use remains challenged by the risk of severe toxicities in a pretreated population....
| Main Authors: | , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2023-02-01
|
| Series: | Cancer Medicine |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/cam4.5143 |
| _version_ | 1797903073187725312 |
|---|---|
| author | Josselin Annic Hélène Babey Romain Corre Renaud Descourt Gilles Quéré Emmanuelle Renaud Mickaël Lambert Pierre Le Noac'h Estelle Dhamelincourt Jessica Nguyen Alicia Vu Vincent Bourbonne Gilles Robinet Margaux Geier |
| author_facet | Josselin Annic Hélène Babey Romain Corre Renaud Descourt Gilles Quéré Emmanuelle Renaud Mickaël Lambert Pierre Le Noac'h Estelle Dhamelincourt Jessica Nguyen Alicia Vu Vincent Bourbonne Gilles Robinet Margaux Geier |
| author_sort | Josselin Annic |
| collection | DOAJ |
| description | Abstract Background Few therapeutic options are approved as second‐line treatment after failure of platinum‐based chemotherapy for patients with extensive‐stage small‐cell lung cancer (ES‐SCLC). Topotecan widespread use remains challenged by the risk of severe toxicities in a pretreated population. Little is known about the efficacy and safety of epirubicin–paclitaxel doublet in second‐line and beyond and especially cerebral outcomes. Methods EpiTax is a retrospective multicenter observational real‐life study. We evaluated the efficacy of epirubicin 90 mg/m2 combined with paclitaxel 175 mg/m2 every 3 weeks in SCLC patients after failure of at least one line of platinum‐based chemotherapy. The primary endpoint was progression‐free survival (PFS). Secondary endpoints were overall survival (OS), objective response rate (ORR), disease control rate (DCR), intracranial control rate (ICR), and safety. Results A total of 29 patients were included. The median of previous systemic therapy lines was 2 (1–4). Eleven patients received the treatment in the second line. Characteristics of patients were a median age of 60 years (45–77), 65.5% of males with 72.4% of PS 0–1. Fifteen patients had a history of brain metastases. Median PFS and OS achieved 11.0 (95% CI, 8.1–16.3) and 23 (95% CI, 14.1–29.6) weeks, respectively. ORR was 34.5% and DCR was 55.2%. ICR was 3/15 (20%). Grade 3–4 adverse events were mainly hematological and concerned 7 patients. No case of febrile neutropenia or toxic death was reported. Conclusion Epirubicin–paclitaxel association highlighted promising efficacy with PFS and OS of 11 and 23 weeks, respectively, ORR of 34.5%, and a tolerable safety profile. This doublet could represent another valuable therapeutic option for ES‐SCLC patients treated in the second line and beyond. |
| first_indexed | 2024-04-10T09:27:13Z |
| format | Article |
| id | doaj.art-028cf8b6cb10454fb7e8bdaca0e1db21 |
| institution | Directory Open Access Journal |
| issn | 2045-7634 |
| language | English |
| last_indexed | 2024-04-10T09:27:13Z |
| publishDate | 2023-02-01 |
| publisher | Wiley |
| record_format | Article |
| series | Cancer Medicine |
| spelling | doaj.art-028cf8b6cb10454fb7e8bdaca0e1db212023-02-19T18:54:07ZengWileyCancer Medicine2045-76342023-02-011232658266510.1002/cam4.5143Real‐life second‐line epirubicin–paclitaxel regimen as treatment of relapsed small‐cell lung cancer: EpiTax studyJosselin Annic0Hélène Babey1Romain Corre2Renaud Descourt3Gilles Quéré4Emmanuelle Renaud5Mickaël Lambert6Pierre Le Noac'h7Estelle Dhamelincourt8Jessica Nguyen9Alicia Vu10Vincent Bourbonne11Gilles Robinet12Margaux Geier13Department of Medical Oncology, CHRU Morvan University Hospital Brest FranceDepartment of Medical Oncology, CHRU Morvan University Hospital Brest FranceDepartment of Pulmonary Diseases CH Cornouaille Quimper FranceDepartment of Medical Oncology, CHRU Morvan University Hospital Brest FranceDepartment of Medical Oncology, CHRU Morvan University Hospital Brest FranceDepartment of Medical Oncology, CHRU Morvan University Hospital Brest FranceDepartment of Medical Oncology, CHRU Morvan University Hospital Brest FranceDepartment of Medical Oncology, CHRU Morvan University Hospital Brest FranceDepartment of Medical Oncology, CHRU Morvan University Hospital Brest FranceDepartment of Medical Oncology, CHRU Morvan University Hospital Brest FranceDepartment of Radiation Oncology University Hospital Brest FranceDepartment of Radiation Oncology University Hospital Brest FranceDepartment of Medical Oncology, CHRU Morvan University Hospital Brest FranceDepartment of Medical Oncology, CHRU Morvan University Hospital Brest FranceAbstract Background Few therapeutic options are approved as second‐line treatment after failure of platinum‐based chemotherapy for patients with extensive‐stage small‐cell lung cancer (ES‐SCLC). Topotecan widespread use remains challenged by the risk of severe toxicities in a pretreated population. Little is known about the efficacy and safety of epirubicin–paclitaxel doublet in second‐line and beyond and especially cerebral outcomes. Methods EpiTax is a retrospective multicenter observational real‐life study. We evaluated the efficacy of epirubicin 90 mg/m2 combined with paclitaxel 175 mg/m2 every 3 weeks in SCLC patients after failure of at least one line of platinum‐based chemotherapy. The primary endpoint was progression‐free survival (PFS). Secondary endpoints were overall survival (OS), objective response rate (ORR), disease control rate (DCR), intracranial control rate (ICR), and safety. Results A total of 29 patients were included. The median of previous systemic therapy lines was 2 (1–4). Eleven patients received the treatment in the second line. Characteristics of patients were a median age of 60 years (45–77), 65.5% of males with 72.4% of PS 0–1. Fifteen patients had a history of brain metastases. Median PFS and OS achieved 11.0 (95% CI, 8.1–16.3) and 23 (95% CI, 14.1–29.6) weeks, respectively. ORR was 34.5% and DCR was 55.2%. ICR was 3/15 (20%). Grade 3–4 adverse events were mainly hematological and concerned 7 patients. No case of febrile neutropenia or toxic death was reported. Conclusion Epirubicin–paclitaxel association highlighted promising efficacy with PFS and OS of 11 and 23 weeks, respectively, ORR of 34.5%, and a tolerable safety profile. This doublet could represent another valuable therapeutic option for ES‐SCLC patients treated in the second line and beyond.https://doi.org/10.1002/cam4.5143cerebral efficacyepirubicinpaclitaxelreal lifesmall‐cell lung cancer |
| spellingShingle | Josselin Annic Hélène Babey Romain Corre Renaud Descourt Gilles Quéré Emmanuelle Renaud Mickaël Lambert Pierre Le Noac'h Estelle Dhamelincourt Jessica Nguyen Alicia Vu Vincent Bourbonne Gilles Robinet Margaux Geier Real‐life second‐line epirubicin–paclitaxel regimen as treatment of relapsed small‐cell lung cancer: EpiTax study Cancer Medicine cerebral efficacy epirubicin paclitaxel real life small‐cell lung cancer |
| title | Real‐life second‐line epirubicin–paclitaxel regimen as treatment of relapsed small‐cell lung cancer: EpiTax study |
| title_full | Real‐life second‐line epirubicin–paclitaxel regimen as treatment of relapsed small‐cell lung cancer: EpiTax study |
| title_fullStr | Real‐life second‐line epirubicin–paclitaxel regimen as treatment of relapsed small‐cell lung cancer: EpiTax study |
| title_full_unstemmed | Real‐life second‐line epirubicin–paclitaxel regimen as treatment of relapsed small‐cell lung cancer: EpiTax study |
| title_short | Real‐life second‐line epirubicin–paclitaxel regimen as treatment of relapsed small‐cell lung cancer: EpiTax study |
| title_sort | real life second line epirubicin paclitaxel regimen as treatment of relapsed small cell lung cancer epitax study |
| topic | cerebral efficacy epirubicin paclitaxel real life small‐cell lung cancer |
| url | https://doi.org/10.1002/cam4.5143 |
| work_keys_str_mv | AT josselinannic reallifesecondlineepirubicinpaclitaxelregimenastreatmentofrelapsedsmallcelllungcancerepitaxstudy AT helenebabey reallifesecondlineepirubicinpaclitaxelregimenastreatmentofrelapsedsmallcelllungcancerepitaxstudy AT romaincorre reallifesecondlineepirubicinpaclitaxelregimenastreatmentofrelapsedsmallcelllungcancerepitaxstudy AT renauddescourt reallifesecondlineepirubicinpaclitaxelregimenastreatmentofrelapsedsmallcelllungcancerepitaxstudy AT gillesquere reallifesecondlineepirubicinpaclitaxelregimenastreatmentofrelapsedsmallcelllungcancerepitaxstudy AT emmanuellerenaud reallifesecondlineepirubicinpaclitaxelregimenastreatmentofrelapsedsmallcelllungcancerepitaxstudy AT mickaellambert reallifesecondlineepirubicinpaclitaxelregimenastreatmentofrelapsedsmallcelllungcancerepitaxstudy AT pierrelenoach reallifesecondlineepirubicinpaclitaxelregimenastreatmentofrelapsedsmallcelllungcancerepitaxstudy AT estelledhamelincourt reallifesecondlineepirubicinpaclitaxelregimenastreatmentofrelapsedsmallcelllungcancerepitaxstudy AT jessicanguyen reallifesecondlineepirubicinpaclitaxelregimenastreatmentofrelapsedsmallcelllungcancerepitaxstudy AT aliciavu reallifesecondlineepirubicinpaclitaxelregimenastreatmentofrelapsedsmallcelllungcancerepitaxstudy AT vincentbourbonne reallifesecondlineepirubicinpaclitaxelregimenastreatmentofrelapsedsmallcelllungcancerepitaxstudy AT gillesrobinet reallifesecondlineepirubicinpaclitaxelregimenastreatmentofrelapsedsmallcelllungcancerepitaxstudy AT margauxgeier reallifesecondlineepirubicinpaclitaxelregimenastreatmentofrelapsedsmallcelllungcancerepitaxstudy |